Hepatocellular carcinoma (HCC) is the fifth most common malignancy and the second
leading cause of cancer-related mortality worldwide. This review is an updated version that …

Hepatocellular carcinoma is the most common type of malignant tumour in Asia. Treatment
is decided according to the staging system with information on tumour burden and liver …

中国人群的肝癌存在生存率低, 死亡率高的情况, 如何有效降低肝癌相关负担仍是中国公共卫生
和慢性病防控领域亟待解决的重大问题, 而肝癌人群筛查策略优化是值得持续探索的重要抓手和 …

Background Using data from the global burden of disease (GBD) between 1990 and 2019 to
report the leading etiological factors and hazards for liver cancer by HBV (LCHB), HCV …

Background Atezolizumab-bevacizumab (atezo-bev) is recommended as first-line therapy
for patients with unresectable hepatocellular carcinoma (uHCC). However, its effectiveness …

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and
represents a classic paradigm of inflammation-related cancer. Various inflammation-related …

The proportions of patients with hepatocellular carcinoma (HCC) involving portal vein tumor
thrombus (PVTT) varies greatly in different countries or regions, ranging from 13% to 45 …

Background Atezolizumab-bevacizumab (atezo/bev) combination is a recommended first-
line systemic therapy for unresectable hepatocellular carcinoma (uHCC). There are no …

Background The therapeutic value of repeat hepatic resection (rHR) or radiofrequency
ablation (RFA) for recurrent hepatocellular carcinoma (HCC) is unknown. This study aimed …

Hepatocellular carcinoma (HCC) presents significant treatment challenges despite
considerable advancements in its management. The Indian National Association for the …